Agenus Inc

NASDAQ:AGENUnited States

Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.

Contact Information

Headquarters

3 Forbes RdLEXINGTON, MA, United States 02421-7305

Phone

781-674-4400

Fax

781-674-4200

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder

Garo Armen

Principal Financial Officer, Principal Accounting Officer, Vice President – Finance

Christine Klaskin

Chief Medical Officer

Steven O'Day

Head of Regulatory

Eric Olson

Lead Independent Director

Timothy Wright